Gregory Renza
Stock Analyst at Truist Financial
(4.89)
# 290
Out of 4,673 analysts
811
Total ratings
59%
Success rate
21%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Maintained: Buy | n/a | $17.00 | - | 5 | Aug 21, 2026 | |
| FULC Fulcrum Therapeutics | Maintained: Hold | n/a | $3.83 | - | 18 | Aug 18, 2026 | |
| PCRX Pacira BioSciences | Initiated Coverage: Buy | $26 → $30 | $24.67 | +21.61% | 32 | Aug 17, 2026 | |
| GMAB Genmab | Maintained: Buy | n/a | $33.45 | - | 6 | Aug 12, 2026 | |
| CATX Perspective Therapeutics | Maintained: Buy | $11 | $3.30 | +233.33% | 19 | Aug 11, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | n/a | $254.28 | - | 42 | Aug 11, 2026 | |
| AGIO Agios Pharmaceuticals | Maintained: Buy | n/a | $33.09 | - | 45 | Aug 11, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $39 | $24.29 | +60.56% | 36 | Aug 11, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $32 | $28.67 | +11.61% | 6 | Aug 11, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $231 | $209.46 | +10.28% | 7 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $85 | $79.81 | +6.50% | 22 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $6.93 | +87.59% | 28 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $52 | $54.08 | -3.85% | 35 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $4.15 | +44.58% | 38 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $27.80 | - | 34 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $416 → $418 | $374.47 | +11.62% | 17 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $340 → $362 | $439.33 | -17.60% | 39 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $156 → $150 | $146.12 | +2.66% | 16 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $63 → $59 | $39.67 | +48.73% | 33 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $769 → $772 | $834.04 | -7.44% | 13 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 | $4.37 | +60.18% | 9 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 | $33.89 | +144.91% | 2 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $34 | $26.72 | +27.25% | 27 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $135 → $155 | $114.95 | +34.84% | 12 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $29.50 | n/a | 57 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $0.9966 | n/a | 24 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $1.18 | n/a | 36 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $6.89 | n/a | 23 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 | $4.82 | n/a | 23 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $48 → $46 | $0.716 | n/a | 8 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $0.5015 | n/a | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $13 | $8.20 | n/a | 14 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $38 | $51.58 | n/a | 26 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,160 → $180 | $19.83 | n/a | 11 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $80 | $0.6403 | n/a | 18 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 → $15 | $0.000001 | n/a | 14 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $348 | $216.78 | n/a | 1 | Sep 8, 2015 |
Ascentage Pharma Group International
Aug 21, 2026
Maintained: Buy
Price Target: n/a
Current: $17.00
Upside: -
Fulcrum Therapeutics
Aug 18, 2026
Maintained: Hold
Price Target: n/a
Current: $3.83
Upside: -
Pacira BioSciences
Aug 17, 2026
Initiated Coverage: Buy
Price Target: $26 → $30
Current: $24.67
Upside: +21.61%
Genmab
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $33.45
Upside: -
Perspective Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $11
Current: $3.30
Upside: +233.33%
Jazz Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $254.28
Upside: -
Agios Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $33.09
Upside: -
Viridian Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $39
Current: $24.29
Upside: +60.56%
Zymeworks
Aug 11, 2026
Maintained: Buy
Price Target: $32
Current: $28.67
Upside: +11.61%
Revolution Medicines
Aug 11, 2026
Reiterated: Buy
Price Target: $231
Current: $209.46
Upside: +10.28%
Aug 11, 2026
Maintained: Buy
Price Target: $85
Current: $79.81
Upside: +6.50%
Aug 7, 2026
Maintained: Buy
Price Target: $13
Current: $6.93
Upside: +87.59%
Aug 6, 2026
Maintained: Hold
Price Target: $52
Current: $54.08
Upside: -3.85%
Aug 6, 2026
Maintained: Buy
Price Target: $6
Current: $4.15
Upside: +44.58%
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $27.80
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: $416 → $418
Current: $374.47
Upside: +11.62%
Aug 5, 2026
Maintained: Hold
Price Target: $340 → $362
Current: $439.33
Upside: -17.60%
Aug 5, 2026
Reiterated: Buy
Price Target: $156 → $150
Current: $146.12
Upside: +2.66%
Aug 5, 2026
Reiterated: Buy
Price Target: $63 → $59
Current: $39.67
Upside: +48.73%
Jul 31, 2026
Maintained: Buy
Price Target: $769 → $772
Current: $834.04
Upside: -7.44%
Jul 31, 2026
Maintained: Hold
Price Target: $7
Current: $4.37
Upside: +60.18%
Jul 30, 2026
Maintained: Buy
Price Target: $83
Current: $33.89
Upside: +144.91%
Jul 10, 2026
Reiterated: Buy
Price Target: $32 → $34
Current: $26.72
Upside: +27.25%
Jul 2, 2026
Maintained: Buy
Price Target: $135 → $155
Current: $114.95
Upside: +34.84%
May 19, 2025
Reiterated: Buy
Price Target: $26
Current: $29.50
Upside: n/a
May 14, 2025
Maintained: Buy
Price Target: $8
Current: $0.9966
Upside: n/a
May 13, 2025
Maintained: Hold
Price Target: $5
Current: $1.18
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: $16
Current: $6.89
Upside: n/a
May 13, 2025
Maintained: Hold
Price Target: $20
Current: $4.82
Upside: n/a
May 12, 2025
Maintained: Buy
Price Target: $48 → $46
Current: $0.716
Upside: n/a
May 7, 2025
Maintained: Buy
Price Target: $16
Current: $0.5015
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: $12 → $13
Current: $8.20
Upside: n/a
May 6, 2025
Maintained: Hold
Price Target: $38
Current: $51.58
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: $2,160 → $180
Current: $19.83
Upside: n/a
Mar 16, 2022
Maintained: Hold
Price Target: $5 → $80
Current: $0.6403
Upside: n/a
Nov 12, 2021
Maintained: Hold
Price Target: $1 → $15
Current: $0.000001
Upside: n/a
Sep 8, 2015
Rated: Buy
Price Target: $348
Current: $216.78
Upside: n/a